Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer
Positive Phase 1 results for LTG-001, Latigo’s potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to be well tolerated with rapid absorption Dr. Singla brings world-class expertise in analgesics, pain management, and clinical development to accelerate Company’s pipeline of non-opioid pain…